Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
NCT02860923
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
42
Enrollment
OTHER
Sponsor class
Conditions
Craniopharyngiomas
Hypothalamic Obesity
Interventions
DRUG:
Exenatide
DRUG:
Placebo
Sponsor
University Hospital, Bordeaux